Tag

China Archives | Page 124 of 199 | Smartkarma

China: Beijing Tongrentang Co A, China Conch Environment Protection Holdings, Huadong Medicine Co Ltd A and more

By | China, Daily Briefs

In today’s briefing:

  • SSE180/​​SSE380 Index Rebalance: Potential MSCI/​FTSE Adds & Deletes
  • Conch Environment (587 HK): Don’t Overly Bet on the Blue Sky Scenario
  • Huadong Medicine Co Ltd (000963.CH) – A “Dark Horse” to Reverse Performance Dilemma

SSE180/​​SSE380 Index Rebalance: Potential MSCI/​FTSE Adds & Deletes

By Brian Freitas

  • There are 18 changes to the SSE180 Index and 38 changes to the SSE380 Index that will be implemented at the close of trading on 9 June.
  • There will be 9 deletions from the MSCI Standard Index and 22 deletions from the FTSE All-World/All-Cap indices at the close on 9 June.
  • Currently, 16 stocks meet the threshold/are close for inclusion in the MSCI China Index while there are 38 stocks that meet the threshold for inclusion in the FTSE All-World/All-Cap indices.

Conch Environment (587 HK): Don’t Overly Bet on the Blue Sky Scenario

By Osbert Tang, CFA

  • The sharp plunge in share price of China Conch Environment Protection Holdings (587 HK) has not yet brought its valuations back to more reasonable levels and we see more downside.
  • Its 10.1x PER for FY22F is at a significant premium over peer average. Even taking into account the impressive ROE, we still cannot find justifications for its high P/B multiple.  
  • Negative catalysts include overly aggressive expansion target, slower profit growth than rise in capacity and surge in gearing and finance costs – they will potentially lead to earnings disappointment.

Huadong Medicine Co Ltd (000963.CH) – A “Dark Horse” to Reverse Performance Dilemma

By Xinyao (Criss) Wang

  • The most recent two quarters have maintained positive growth. It is of great significance for Huadong, who once suffered a significant decline and now in a critical period of transformation.
  • The large growth potential of medical cosmetology and industrial microbiology would be important driver for future development. It’s also wise to strike a balance between current performance and future strategy.
  • Huadong’s revenue growth would be above 10% in next few years. It would have higher valuation than Imeik. Investors are advised to follow Huadong. It could be a “dark horse”.

Before it’s here, it’s on Smartkarma

China: Jinko Solar, Shanghai Pudong Development Bank Co., TBEA Co Ltd A, Apple Inc, Dongzheng Automotive Finance and more

By | China, Daily Briefs

In today’s briefing:

  • STAR50 Index Rebalance: Dear Index Committee…
  • SSE50 Index Rebalance: Some Large Impact Changes
  • CSI300 Index Rebalance: Big Sector Shift with 28 Changes
  • Harding Loevner Global Equity Fund Q1 2022 Letter
  • Dongzheng’s Potential MGO Price from SAIC at HK$1.2430

STAR50 Index Rebalance: Dear Index Committee…

By Brian Freitas

  • The index committee has continued to use a 6 month minimum listing history leading to five changes to the SSE STAR50 (STAR50 INDEX) in June.
  • One way turnover is estimated at 8.56% and will result in a one-way trade of CNY 3,496m. Passive trackers will need to trade between 2-6 days ADV on the adds/deletes.
  • The inclusions have outperformed the deletions and the CSI500 Index since the end of the review period with all inclusions moving higher over the period.

SSE50 Index Rebalance: Some Large Impact Changes

By Brian Freitas

  • There are 5 changes for the SSE50 Index that will be implemented at the close on 9 June. The impact is pretty chunky on a few deletions.
  • Apart from the passive assets tracking the index, there are some liquid index futures and the impact on the stocks will be larger than just the headline numbers.
  • The adds underperformed the deletes in March and April but have come roaring back in May. Playing the trade via long/short pairs could provide better risk adjusted returns.

CSI300 Index Rebalance: Big Sector Shift with 28 Changes

By Brian Freitas

  • There are 28 changes for the Shanghai Shenzhen CSI 300 Index (SHSZ300 INDEX) at the upcoming rebalance that will be implemented at the close of trading on 9 June.
  • We had forecast nearly all the changes, though the index committee seems to have used discretion in deciding not to add three Distillers to the index, leading to other changes.
  • There’s a large sector skew with Industrials, Information Technology and Materials stocks taking 17 more spots in the index, while Health Care and Financials lose 9 and 5 spots respectively.

Harding Loevner Global Equity Fund Q1 2022 Letter

By Fund Newsletters

  • Harding Loevner has been investing globally in high-quality, growing businesses based on disciplined industry research since 1989.
  • Stock markets fell in the quarter, as the world watched in horror Russia’s invasion of Ukraine.
  • China-based WuXi Biologics illustrates the perfect storm of macro issues pressuring the share prices of our rapidly growing companies.
  • As questions mount whether globalization has reached a tipping point, companies are taking full advantage of the many advances occurring across the industrial automation landscape— propelling leadingp roviders of “Industry 4.0” solutions onto favorable growth paths.

Dongzheng’s Potential MGO Price from SAIC at HK$1.2430

By Arun George

  • The potential MGO price is HK$1.2430 per H Share vs Dongzheng Automotive Finance (2718 HK)’s previously noted HK$1.294 per H Share due to the change in RMB/HK$ rates.
  • The completion procedures for the auction will take place within six months. Approvals have low risk as the SAIC Motor (600104 CH)’s controlling shareholder is owned by the Shanghai SASAC.
  • At the last close and for a 1 November completion, the gross and annualised spread to the MGO price is 5.3% and 12.7%, respectively.

Before it’s here, it’s on Smartkarma

China: Dongzheng Automotive Finance, CanSino Biologics Inc, Kweichow Moutai, Beijing Enterprises Urban Resources, Beauty Farm Medical and Health Industry, AIA Group Ltd, Lenovo, Agile Property Holdings and more

By | China, Daily Briefs

In today’s briefing:

  • SAIC’s Unconditional Offer For Dongzheng
  • Shanghai/​Shenzhen Southbound Connect: Weekly Moves (27 May 2022)
  • Shanghai/​Shenzhen Northbound Connect: Weekly Moves (27 May 2022)
  • Beijing Enterprises Urban Resources’ MGO Open, First Closing Date 17 June
  • Beauty Farm Medical and Health Industry Pre-IPO: Near-Term Operating Environment Is Not Beautiful
  • Harding Loevner Emerging Markets Equity Fund Q1 2022 Letter
  • Harding Loevner Emerging Markets Equity Fund Q1 2022 Letter
  • Weekly Wrap – 27 May 2022
  • Chinese Property Weekly – 27 May 2022 – Lucror Analytics
  • Chinese Property Weekly – 27 May 2022 – Lucror Analytics

SAIC’s Unconditional Offer For Dongzheng

By David Blennerhassett


Shanghai/​Shenzhen Southbound Connect: Weekly Moves (27 May 2022)

By David Blennerhassett

  • Inside is a recap of movements in the last week relating to the Shanghai and Shenzhen-Hong Kong Stock Connect facilities, broken down by company and industry. 
  • Overall, net inflow was ~US$1.1bn, split evenly (roughly) between Shanghai and Shenzhen. 
  • The largest inflows were into  China Mobile (941 HK) and CNOOC Ltd (883 HK). The largest outflows were in Kuaishou Technology (1024 HK) and BYD (1211 HK).

Shanghai/​Shenzhen Northbound Connect: Weekly Moves (27 May 2022)

By David Blennerhassett


Beijing Enterprises Urban Resources’ MGO Open, First Closing Date 17 June

By Arun George

  • Beijing Enterprises Urban Resources (3718 HK) composite document is out with the MGO’s first closing date of 17 June. The IFA considers Beijing Enterprises Water Group (371 HK)‘s offer fair. 
  • The MGO is conditional on the offeror and concert parties holding more than 50% of the voting rights. With the offeror currently at 44.16%, the MGO should become unconditional. 
  • At last close and for a 28 June payment, the gross and annualised spread to the MGO price (including final dividend) of HK$0.81 per share is 2.5% and 31.5%, respectively.

Beauty Farm Medical and Health Industry Pre-IPO: Near-Term Operating Environment Is Not Beautiful

By Tina Banerjee

  • Beauty Farm Medical and Health Industry (BFM HK), second largest body and skin care service provider in China has filed for IPO on the Hong Kong Stock Exchange.  
  • Large and growing addressable market, comprehensive service offering, nationwide store network, and sound financial position are the major strengths of the company.
  • BFM’s operation faces uncertainties over COVID and related restrictions. This IPO is not expected to see listing gain unless general market condition and China’s economic growth outlook improve.

Harding Loevner Emerging Markets Equity Fund Q1 2022 Letter

By Fund Newsletters

  • Harding Loevner has been investing globally in high-quality, growing businesses based on disciplined industry research since 1989.
  • Emerging Markets (EMs) declined sharply, primarily due to the collapse in Russian equities brought about by economic sanctions against Russia because of its invasion of Ukraine, as well as poor performance in China.
  • The EM landscape is currently fogged by an exceptional confluence of risks: armed conflict in Ukraine, inflation, rising interest rates, volatile commodity prices, and concerns about food and energy security.
  • Although we made only a handful of transactions this quarter, the portfolio’s profile changed significantly because of the write-down of our Russian holdings and the outsized returns of stocks benefiting from commodity price inflation.

Harding Loevner Emerging Markets Equity Fund Q1 2022 Letter

By Fund Newsletters

  • Harding Loevner has been investing globally in high-quality, growing businesses based on disciplined industry research since 1989.
  • Emerging Markets (EMs) declined sharply, primarily due to the collapse in Russian equities brought about by economic sanctions against Russia because of its invasion of Ukraine, as well as poor performance in China.
  • The EM landscape is currently fogged by an exceptional confluence of risks: armed conflict in Ukraine, inflation, rising interest rates, volatile commodity prices, and concerns about food and energy security.
  • Although we made only a handful of transactions this quarter, the portfolio’s profile changed significantly because of the write-down of our Russian holdings and the outsized returns of stocks benefiting from commodity price inflation.

Weekly Wrap – 27 May 2022

By Charles Macgregor

Lucror Analytics Weekly Wraps provide an overview of all Morning Views comments and reports published by our analyst team in the past week, and also showcase a list of the most-read reports.

In this Insight:

  1. Adani Ports & Special Economic Zone
  2. Yanzhou Coal Mining Company Limited H
  3. Vedanta Resources
  4. Indika Energy
  5. Pakuwon Jati

and more…


Chinese Property Weekly – 27 May 2022 – Lucror Analytics

By Charles Macgregor

The Chinese Property Weekly focuses on providing updates in the Chinese real-estate sector, including recent regulatory and company developments, top and bottom performers, rating actions, as well as a list of bond maturities in the next 30 days.


Chinese Property Weekly – 27 May 2022 – Lucror Analytics

By Charles Macgregor

The Chinese Property Weekly focuses on providing updates in the Chinese real-estate sector, including recent regulatory and company developments, top and bottom performers, rating actions, as well as a list of bond maturities in the next 30 days.


Before it’s here, it’s on Smartkarma

China: Tencent, Alibaba Group, Shenzhen Expressway Co H, Lenovo, Activision Blizzard and more

By | China, Daily Briefs

In today’s briefing:

  • Hang Seng Index Constituents
  • Alibaba (9988 HK): Well Controlled Expense in 4Q22 and Forthcoming Turning Point in June, Buy
  • Shenzhen Expressway (548 HK): Cautiously Optimistic
  • Morning Views Asia: Adani Ports & Special Economic Zone, Bharti Airtel, Lenovo, Vedanta Resources
  • FPA U.S. Core Equity Fund Q1 2022 Commentary

Hang Seng Index Constituents

By Untying The Gordian Knot

  • The Hang Seng index constituents have moved away from just local Hong Kong shares to being dominated by China H and China-centric shares
  • Focusing on these constituents adds much value, especially with shifting liquidity away from US-listed ADS to HKEX listed shares.
  • It brings together a more diverse investor base ranging from local Hong Kong, mainland China and the rest of the world.

Alibaba (9988 HK): Well Controlled Expense in 4Q22 and Forthcoming Turning Point in June, Buy

By Ming Lu

  • Operating margin improved in 4Q22 due to well controlled expenses in minor businesses.
  • We believe the state council meeting will provide a turning point in June.
  • We set an upside of 31% and a price target at HK$106.

Shenzhen Expressway (548 HK): Cautiously Optimistic

By Osbert Tang, CFA

  • Shenzhen Expressway Co H (548 HK) guided that many drivers are presented for the rest of the year to support growth, after a 24% YoY decline in 1Q22 net profit. 
  • Toll road business should benefit from organic growth and project completions, while clean energy and waste treatment businesses will experience astronomical growth from capacity acquisitions. 
  • There exists room to leverage up for growth as liabilities-to-asset ratio is still 11pp below its tolerance level of 65%. Besides below-average PERs, FY22F yield of 10% is attractive too.

Morning Views Asia: Adani Ports & Special Economic Zone, Bharti Airtel, Lenovo, Vedanta Resources

By Charles Macgregor

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.


FPA U.S. Core Equity Fund Q1 2022 Commentary

By Fund Newsletters

  • FPA is a Los Angeles-based institutional money management firm practicing a disciplined approach to value investing, prudently seeking superior long-term returns while maintaining a focus on capital preservation.
  • In the first quarter of 2022, the FPA U.S. Core Equity Fund, Inc.’s (“Fund”) performance was -12.25% (-12.01% before fees and expenses).
  • I believe secularly growing mid- to large-capitalization companies trading at compelling valuations will continue to be a favorable place to invest for the long-term—especially relative to U.S. Treasuries and other investment alternatives.

Before it’s here, it’s on Smartkarma

China: Jiayuan Services Holdings Limited, NetEase Inc, Dongzheng Automotive Finance, Imeik Technology Development, Powerlong Real Estate Holdings and more

By | China, Daily Briefs

In today’s briefing:

  • Jinke & Jiayuan: Pledged Shares And Leveraged Property Developers
  • NetEase (9999 HK): Steady Without New Games in 1Q22 and New Games in Pipeline, Buy
  • SAIC Wins the Auction for the 71.04% Stake in Dongzheng, MGO Upcoming
  • Imeik Technology Development (300896.CH) – Superficial Prosperity Hardly Masks Underlying Risks
  • Morning Views Asia: Powerlong Commercial Management Holdings

Jinke & Jiayuan: Pledged Shares And Leveraged Property Developers

By David Blennerhassett

  • On the 21 May, Jinke Property (000656 CH) announced the forced sale of shares by its controlling shareholder. One day later, Jiayuan International (2768 HK) announced a similar event. 
  • Jinke’s 52.3%-owned Jinke Smart (9666 HK) has now announced an agreement to acquire Jiayuan International’s 73.56% stake in property service play Jiayuan Services Holdings (1153 HK). No price was announced.
  • In the past month, Jinke Property is down 24%, Jinke Smart 23%, Jiayuan International 54% and Jiayuan Services 80%. Jiayuan International and Jiayuan Services remain suspended.

NetEase (9999 HK): Steady Without New Games in 1Q22 and New Games in Pipeline, Buy

By Ming Lu

  • Total revenue grew by 15% YoY and operating margin improved YoY in 1Q22.
  • The authorities began to grant licenses and new games will be launched in China and overseas.
  • We set an upside of 25% and a price target at US$120. Buy.

SAIC Wins the Auction for the 71.04% Stake in Dongzheng, MGO Upcoming

By Arun George


Imeik Technology Development (300896.CH) – Superficial Prosperity Hardly Masks Underlying Risks

By Xinyao (Criss) Wang

  • Imeik keeps its outstanding financial performance in 2021/2022Q1. On the surface, it looks prosperous, but its development strategy, product layout and resilience in front of risks would bring many uncertainties.
  • Considering the pandemic/lockdown and a slowing economy in China, the revenue growth in 2022 could fall to about 50%, then to about 40% and 30% in 2023 and 2024 respectively.
  • Imeik’s valuation is “unreasonably high”, which is expected to be lower than Bloomage in the future. Anything that deviates from fundamentals would inevitably return to the origin. 

Morning Views Asia: Powerlong Commercial Management Holdings

By Charles Macgregor

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.


Before it’s here, it’s on Smartkarma

China: Dongzheng Automotive Finance, Xpeng, Kuaishou Technology, Cosco Shipping Energy Transportation Co. Ltd. (H) and more

By | China, Daily Briefs

In today’s briefing:

  • Shh! SAIC’s Unconditional Offer For Dongzheng (2718 HK)
  • XPENG Slide to 18 Major Pivot Point
  • Kuaishou – Continued Drop in Operating Losses with Upside Potential
  • Kuaishou (1024 HK): 1Q22, Strong Revenue and Shrinking Loss, 19% Upside
  • COSCO Shipping Energy (1138 HK): Ahead of the Curve…but Too Much

Shh! SAIC’s Unconditional Offer For Dongzheng (2718 HK)

By David Blennerhassett


XPENG Slide to 18 Major Pivot Point

By Thomas Schroeder

  • XPEV (US ADR) is forming a compelling positive wedge but faces a test of the critical 18 macro dual low support where a trading bounce is expected.
  • Sell volumes rose on the 25 rejection, calling for a test on the key 18/19 support zone.
  • RSI sub 30 target does suggest XPEV breaks 18 support after a tradable bounce with 24/25 the key hurdle. 31 represents MT resistance. 9868 HK linked levels.

Kuaishou – Continued Drop in Operating Losses with Upside Potential

By Shifara Samsudeen, ACMA, CGMA

  • Kuaishou reported 1Q2022 results on Tuesday. Revenue grew 23.8% YoY to RMB21.1bn while reported operating losses declined to RMB5.6bn (27% of revenue) from RMB7.3bn (43% of revenues) in 1Q2021.
  • Adjusted operating losses for the quarter further dropped to 24% of revenues from 48% of revenues in 1Q2021 despite drop in livestreaming ARPPU in 1Q2022.
  • Kuaishou’s shares have lost almost 80% since its IPO in February last year due to the regulatory crackdown.

Kuaishou (1024 HK): 1Q22, Strong Revenue and Shrinking Loss, 19% Upside

By Ming Lu

  • Revenue increased by 24% YoY with online marketing, the main business, up 33% YoY.
  • KS operating loss decreased to RMB5.1 bn in 1Q22 from RMB8.2 bn.
  • We set an upside of 19% and a price target of HK$75.00. Buy.

COSCO Shipping Energy (1138 HK): Ahead of the Curve…but Too Much

By Osbert Tang, CFA

  • Share price of Cosco Shipping Energy Transportation Co. Ltd. (H) (1138 HK) has rallied 55.7% over the last four months, and we believe it is now prudent to trim position.
  • P/B valuation is almost at 5-year high and over 2SD above historical average, but ROE for FY22F is still shy of the peak level achieved in such period. 
  • There is downgrade risk for FY22F consensus profit of Rmb1.6bn given 1Q22 profit of just Rmb25m, and near-term retreat in spot rate does not bode well for CSET. 

Before it’s here, it’s on Smartkarma

China: Tongwei Co Ltd A, Sunny Optical, Cloud Village, Bloomage Biotechnology Corporation-A, Evergrande and more

By | China, Daily Briefs

In today’s briefing:

  • FTSE China A50 Index Rebalance Preview: Three Potential Adds/Deletes Due to Ground Rule Change
  • FTSE China 50 Index Rebalance Preview: Adds, Deletes & Capping Changes
  • Cloud Village IPO Lock-Up – Selling the PE Stock (US$350m) Might Solve the Liquidity Issues
  • Bloomage Biotechnology Vs Yunnan Botanee Bio-Technology – Accumulate Richly and Break Forth Vastly
  • Morning Views Asia: Alam Sutera Realty, Evergrande, Greenland Holdings Corp, Indika Energy

FTSE China A50 Index Rebalance Preview: Three Potential Adds/Deletes Due to Ground Rule Change

By Brian Freitas


FTSE China 50 Index Rebalance Preview: Adds, Deletes & Capping Changes

By Brian Freitas


Cloud Village IPO Lock-Up – Selling the PE Stock (US$350m) Might Solve the Liquidity Issues

By Sumeet Singh

  • Cloud Village Inc. (CVI), also known as NetEase Music, raised around US$420m in its Hong Kong IPO in Dec 21. The IPO was almost entirely taken up by cornerstones.
  • The company had also earlier obtained investments from Baidu and Alibaba, along with other mainly PE investors. These investors will be released from their lock-up on 1st Jun 2022.
  • In this note, we will talk about the lock-up dynamics and updates over the past few months.

Bloomage Biotechnology Vs Yunnan Botanee Bio-Technology – Accumulate Richly and Break Forth Vastly

By Xinyao (Criss) Wang

  • Botanee has outstanding performance at the current stage, but WINONA alone is not enough to establish a high moat. Its weak R&D/innovation in raw materials/products would cast doubts on outlook.
  • Bloomage is more R&D oriented and characterized by integration of industrial chain. Its advanced synthetic biology will bring more possibilities for future development.The collagen would be a new growth point.
  • Although with lower net profit margin, Bloomage is expected to have better outlook than Botanee. So, we think Bloomage could have higher valuation than Botanee in the future.  

Morning Views Asia: Alam Sutera Realty, Evergrande, Greenland Holdings Corp, Indika Energy

By Charles Macgregor

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.


Before it’s here, it’s on Smartkarma

China: NIO Inc, Lenovo, HKBN Ltd, JD.com Inc (ADR) and more

By | China, Daily Briefs

In today’s briefing:

  • Hang Seng TECH Index Rebalance: NIO (9866 HK) To Replace ASM Pacific (522 HK)
  • HSCEI Index Rebalance: Lenovo In, Hansoh Out; Sunac Survives (For Now)
  • Index Rebalance & ETF Flow Recap: MSCI, ASX, NIFTY, KRX, PCOMP, HSI, HSCEI, HSTECH, SK Tel, GoTo
  • Asia-Pac Weekly Risk Arb Wrap: Kinetsu World, Hwa Hong, MyDeal, Kito, Virtus Health, Irongate, HKBN
  • ECM Weekly (22nd May 22) – JD, LIC, Delhivery, Leapmotor, Vista, Paradeep, Woori, Hyundai Heavy, NIO

Hang Seng TECH Index Rebalance: NIO (9866 HK) To Replace ASM Pacific (522 HK)

By Brian Freitas


HSCEI Index Rebalance: Lenovo In, Hansoh Out; Sunac Survives (For Now)

By Brian Freitas


Index Rebalance & ETF Flow Recap: MSCI, ASX, NIFTY, KRX, PCOMP, HSI, HSCEI, HSTECH, SK Tel, GoTo

By Brian Freitas

  • Plenty of review announcements after the close on Friday – HSI, HSCEI, HSTECH, FTSE AW/AC, Sensex. Most changes were as expected.
  • There are a lot of review cutoffs on Monday and announcements expected later in the week (KOSPI200, KOSDAQ150, CSI300, STAR50).
  • There were inflows to Hong Kong, Taiwan, Korea and Australia focused ETFs during the week, while there were outflows from China, Japan and India focused ETFs.

Asia-Pac Weekly Risk Arb Wrap: Kinetsu World, Hwa Hong, MyDeal, Kito, Virtus Health, Irongate, HKBN

By David Blennerhassett


ECM Weekly (22nd May 22) – JD, LIC, Delhivery, Leapmotor, Vista, Paradeep, Woori, Hyundai Heavy, NIO

By Sumeet Singh

  • Aequitas Research puts out a weekly update on the deals that were covered by the team recently along with updates for upcoming IPOs.
  • With LIC not delivering and Delhivery needing insurance, combined with the Korean cancellations and HK silence, it looks like its going to be a quiet few weeks for IPOs.
  • On placements, both the Korean deals were a disappointment, despite being well-flagged.

Before it’s here, it’s on Smartkarma

China: JD.com Inc (ADR), Tencent, Li Ning, Taste Gourmet Group, Shanghai Haohai Biological Technology-A, Leapmotor and more

By | China, Daily Briefs

In today’s briefing:

  • JD.com Tencent Distribution – All Prosus Stock Worth US$3.5bn Could Be in CCASS Now
  • Tencent (700 HK): 1Q22, Zero Growth, But Will Recover for New Policies, Upgrade to Buy
  • Tencent 1Q2022– Weaker than Expected
  • Li Ning (2331): Turning Positive.
  • Taste Gourmet: Update Post Management Call / Bullish
  • Shanghai Haohai Biological Technology (688366CH)- Diversified Business Layout Doesn’t Secure Outlook
  • Leapmotor Pre-IPO – The Negatives – Related Party Sanctions, Lags Peers

JD.com Tencent Distribution – All Prosus Stock Worth US$3.5bn Could Be in CCASS Now

By Sumeet Singh

  • On 23rd Dec 2021, Tencent declared a special dividend in the form of distribution in specie of shares of JD.com, making Prosus the third largest shareholder with a 4.2% stake.
  • The actual settlement only happened on 25th Mar. On that day, the bulk of the stock that Tencent distributed moved into CCASS with the exception of shares held by Prosus.
  • In this note, we talk about the shareholding pattern and increase in shares held in CCASS.

Tencent (700 HK): 1Q22, Zero Growth, But Will Recover for New Policies, Upgrade to Buy

By Ming Lu

  • Authorities encourage platform economy and restarted approving the licenses for new games.
  • Fintech just met a high comparison base in 1Q21 and we believe the growth rate will rise.
  • We believe the stock has an upside of 39% for the year end 2022.

Tencent 1Q2022– Weaker than Expected

By Shifara Samsudeen, ACMA, CGMA

  • Tencent (700 HK) reported 1Q2022 results today. Revenue grew 0.1% YoY to RMB135.5bn (vs consensus RMB140.7bn) while reported OP decreased 34% YoY to RMB37.2bn (vs consensus RMB37.3bn).
  • Adjusted OP was down 36% YoY to RMB22.3bn while adjusted OPM declined to 39.2% from 56.1% in the same period a year ago.
  • Tencent’s 1Q2022 revenues were below our estimates of RMB144.3bn which was mainly due to significant drop in Fintech and business services revenues.

Li Ning (2331): Turning Positive.

By Henry Soediarko

  • Q1 22 operating figures are better than the smaller peers although not exactly beating Anta. 
  • Launching the cafe to boost SSSG post-COVID-19 is a positive strategy. 
  • Its valuation is currently trading below its historical highs . Turn positive on Li Ning (2331 HK) .

Taste Gourmet: Update Post Management Call / Bullish

By Sameer Taneja

  • Taste Gourmet Group (8371 HK) held a webinar with Smartkarma on the 17th of May, highlighting the sharp and swift recovery of F&B in Hong Kong. 
  • Post 19th May, eight people can dine in till midnight (vs. four). With mid-May revenue tracking 109% of June 2020 (restrictions were fully relaxed), recovery should be better than expectations.
  • Despite the 13% move yesterday, the stock is still cheap at 5.9x PE FY23 earnings and an 8-10% dividend yield (with a potential for further upgrades). 

Shanghai Haohai Biological Technology (688366CH)- Diversified Business Layout Doesn’t Secure Outlook

By Xinyao (Criss) Wang

  • Haohai’s development is fuelled by a series of acquisitions, which help Haohai establish the existing diversified businesses, but we haven’t seen any growth point with high certainty.
  • Compared with Bloomage and Imeik, Haohai has no competitive advantage in the field of medical aesthetics. It’s also difficult for Haohai to make a substantial breakthrough without obvious product advantages.
  • Although Haohai’s PE/TTM is significantly lower than its peers, due to centralized procurement, Haohai’s valuation could be further lower. Considering the risks, we choose to stay cautious on Haohai.

Leapmotor Pre-IPO – The Negatives – Related Party Sanctions, Lags Peers

By Sumeet Singh

  • Leapmotor (LM) aims to raise around US$1bn in its Hong Kong IPO. LM is a smart EV company based in China, founded in 2015.
  • It focuses on the mid- to high-end segment in China’s NEV market with a price range of RMB150,000-300,000. As of end FY21, it had delivered a total of 52,832 cars.
  • In this note, we talk about the not so positive aspects of the deal.

Before it’s here, it’s on Smartkarma

China: Haier Smart Home Co Ltd, Yunkang Group, JD.com Inc., Semiconductor Manufacturing International Corp (SMIC), Tencent Music, Aier Eye Hospital Group, FTSE China A50 Index, Agile Property Holdings and more

By | China, Daily Briefs

In today’s briefing:

  • Haier Smart Home (6690 HK): Smart Moves
  • Yunkang Group IPO Trading –  Subdued Subscription Rates Combined with Uncertain Future Profitability
  • JD.com (9618 HK): 1Q22 Result, Undervalued Despite of Weak Revenue
  • SMIC (981.HK): The Overall Demand Situation Is Growing Up in 2022.
  • TME – Miss on Revenue and Margins; Earnings Continue to Remain Under Pressure
  • Aier Eye Hospital Group (300015.CH) 2021/2022Q1 Results – Overvaluation and a Risky Outlook
  • China A and HSI Re Short Levels
  • Morning Views Asia: AAC Technologies Holdings, Greenko Energy Holdings, Yuzhou Group

Haier Smart Home (6690 HK): Smart Moves

By Osbert Tang, CFA

  • Besides as nationalistic consumption play, Haier Smart Home (6690 HK) also offers attractive investment theses with bright growth prospects. Despite share price rebound, valuations are still not yet reflecting fundamentals.
  • The surge in demand for refrigerators and freezers during the pandemic-led lockdowns has boosted HSH’s business in 4M22 while it will also reap benefits from Rmb depreciation.
  • The government’s support of healthy development of residential real estate market will be positive towards smart home appliance demand which HSH is set to gain from its leadership position. 

Yunkang Group IPO Trading –  Subdued Subscription Rates Combined with Uncertain Future Profitability

By Clarence Chu

  • Yunkang Group (2325 HK) raised around US$139m in its Hong Kong IPO.
  • On its bookbuild, subscription rates were lackluster and market sentiment hasn’t been the greatest.
  • Similar recent deals with weak subscription rates had seen subdued listing performances by the end of their respective first weeks.

JD.com (9618 HK): 1Q22 Result, Undervalued Despite of Weak Revenue

By Ming Lu

  • JD will continue to close its unprofitable minor businesses in following quarters.
  • The growth rate of total revenue slowed down in 1Q21 due to weak demand of home appliance.
  • We believe JD has a significant upside despite that the revenue growth will continue to slow down.

SMIC (981.HK): The Overall Demand Situation Is Growing Up in 2022.

By Patrick Liao

  • SMIC reported revenue/GM were US$1,869/40% for revenue/GM in 1Q22 respectively. The revenue matched to our expectation, but the GM was exceeding ~8% versus guidance.
  • The outlook is a little bit lower than our expectation for revenue/GM to be US$1860-1,897/37-39% in 2Q22 guidance.
  • The overall demand situation is growing up although inflation, Russia-Ukraine war, and other factors may affect. 

TME – Miss on Revenue and Margins; Earnings Continue to Remain Under Pressure

By Shifara Samsudeen, ACMA, CGMA

  • Tencent Music (TME US) reported 1Q2022 results today. Revenue declined 15% YoY to RMB6.64bn (vs consensus RMB6.69n) while reported OP dropped 35.7% YoY to RMB749m (vs consensus RMB817m).
  • Revenue from Online music services declined YoY for the first time since 2017 while revenue from Social Entertainment services further declined during the quarter.
  • We expect TME’s earnings to remain under pressure with increased competition and regulatory restrictions on livestreaming sector.

Aier Eye Hospital Group (300015.CH) 2021/2022Q1 Results – Overvaluation and a Risky Outlook

By Xinyao (Criss) Wang

  • Aier’s private placement was approved by the Shenzhen Stock Exchange, but we don’t think it signals a complete policy shift that private medical institutions are welcomed by capital markets.
  • The high goodwill impairment risk and medical disputes are great concerns. However, if Aier changes its development mode, its performance growth would probably slow down or becomes uncertain.
  • Aier’s Q2 performance could be affected by pandemic/lockdown. Even after continuous corrections, Aier is still overvalued based on current valuation, which has not priced in all the concerns and risks.

China A and HSI Re Short Levels

By Thomas Schroeder

  • A50 faces key trendline sell/pivot resistance that will cap the rise with HSI nudging back to sell territory with fresh chart lows expected.
  • A50 trendline resistance is the bull/bear inflection point. We look for a sell or rejection near 13,700 if not just under this level for  a test on the 12,400.
  • HSI 21k sell barrier while watching for HK tech rise to run out of steam near 4,500 resistance.

Morning Views Asia: AAC Technologies Holdings, Greenko Energy Holdings, Yuzhou Group

By Charles Macgregor

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.


Before it’s here, it’s on Smartkarma